Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 10, 2022

SELL
$0.61 - $1.84 $6,445 - $19,443
-10,567 Closed
0 $0
Q4 2021

Feb 08, 2022

SELL
$1.16 - $2.74 $11,030 - $26,054
-9,509 Reduced 47.37%
10,567 $12,000
Q3 2021

Nov 12, 2021

SELL
$2.62 - $5.43 $10,694 - $22,165
-4,082 Reduced 16.9%
20,076 $53,000
Q2 2021

Aug 13, 2021

BUY
$5.06 - $8.15 $25,699 - $41,393
5,079 Added 26.62%
24,158 $128,000
Q1 2021

May 14, 2021

BUY
$6.24 - $9.58 $10,370 - $15,921
1,662 Added 9.54%
19,079 $129,000
Q4 2020

Feb 09, 2021

BUY
$6.28 - $8.79 $109,378 - $153,095
17,417 New
17,417 $118,000
Q4 2019

Feb 12, 2020

SELL
$3.36 - $4.81 $39,295 - $56,252
-11,695 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$3.57 - $6.58 $389 - $717
109 Added 0.94%
11,695 $44,000
Q2 2019

Aug 13, 2019

SELL
$4.93 - $8.8 $8,070 - $14,405
-1,637 Reduced 12.38%
11,586 $74,000
Q1 2019

May 15, 2019

BUY
$5.19 - $8.97 $570 - $986
110 Added 0.84%
13,223 $109,000
Q4 2018

Feb 14, 2019

BUY
$4.29 - $9.94 $7,117 - $16,490
1,659 Added 14.48%
13,113 $64,000
Q3 2018

Nov 14, 2018

SELL
$9.54 - $13.87 $3,835 - $5,575
-402 Reduced 3.39%
11,454 $113,000
Q2 2018

Aug 13, 2018

SELL
$13.3 - $17.49 $17,356 - $22,824
-1,305 Reduced 9.92%
11,856 $163,000
Q1 2018

May 14, 2018

SELL
$12.26 - $18.98 $13,829 - $21,409
-1,128 Reduced 7.89%
13,161 $208,000
Q4 2017

Feb 14, 2018

BUY
$13.68 - $23.17 $195,473 - $331,076
14,289
14,289 $264,000

Others Institutions Holding KALA

# of Institutions
1
Shares Held
1
Call Options Held
0
Put Options Held
0

About Kala Pharmaceuticals, Inc.


  • Ticker KALA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 1,464,160
  • Market Cap $9.82M
  • Description
  • Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...
More about KALA
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.